A practical reference on dihexa: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-06 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
== Radioactivity == Natural strontium (Sr) is nonradioactive and nontoxic at levels normally found in the environment, but 90Sr is a radiation hazard. 90Sr undergoes β− decay with a half-life of 28.91 years and a decay energy of 546 keV distributed to an electron, an antineutrino, and 90Y, which in turn undergoes β− decay with a half-life of 64.05 hours and a decay energy of 2.28 MeV distributed to an electron, an antineutrino, and occasionally a gamma ray, leaving stable 90Zr. The gamma-emitting branches are so weak that for most purposes 90Sr and 90Y can be considered pure beta particle emitters.
Sacubitril/valsartan (Entresto/LCZ696), which has been tested against enalapril in patients with heart failure. Sacubitril (AHU-377), a prodrug which is a component of sacubitril/valsartan Sacubitrilat (LBQ657), the active form of sacubitril RB-101, an enkephalinase inhibitor, used in scientific research. UK-414,495 Omapatrilat (dual inhibitor of NEP and angiotensin-converting enzyme) developed by BMS did not receive FDA approval due to angioedema safety concerns. Ecadotril Candoxatril Other dual inhibitors of NEP with ACE/angiotensin receptor were (in 2003) being developed by pharmaceutical companies.
Psylocke is the alias of two connected characters appearing in American comic books published by Marvel Comics, commonly in association with the X-Men. Both characters are depicted as mutants, a subspecies of humans born with an "X-gene" that grants superhuman abilities. In the primary continuity of the Marvel Universe, the first and best-known incarnation of Psylocke is Betsy Braddock (created by Chris Claremont and Herb Trimpe), a British telepath who was introduced as a supporting character for her twin brother Brian in 1976. Betsy adopts the codename "Psylocke" upon joining the X-Men in 1986, and three years later takes on the appearance of a Japanese woman and the abilities of a ninja in a story written by Claremont and illustrated by Jim Lee. This redesign was retroactively revealed in 1993 as the result of a body swap with the ninja assassin Kwannon (created by Fabian Nicieza and Andy Kubert). Following 29 years of publication history, both women were returned to their respective bodies, and Betsy assumed the mantle of Captain Britain from her brother while Kwannon became the second Psylocke. The Ultimate Universe features two versions of Psylocke: Sai and Kanon Sainouchi (both created by Peach Momoko). In addition to their presence in numerous X-related team titles over the decades, both iterations of Psylocke have been featured in various limited series and one-shots. In 1997, Betsy Braddock, as Psylocke, appeared in the 4-issue team-up series Psylocke and Archangel: Crimson Dawn.
== Cause == Occupational exposures constitute the highest risk of toxicity and it is often high for farmers especially those that deal with food grains. It is equally high for firefighters and military personnel, especially those officers that deal in explosives. The risk is also high for arc welders, traffic officers, aerospace staffs and miners as well as those people whose occupations are connected with the nitric acid. Silo-filler's disease is a consequence of exposure to nitrogen dioxide poisoning by farmers dealing with silos. Food grains such as corn and millet, as well as grasses such as alfalfa and some other plant material, produces nitrogen dioxide within hours due to anaerobic fermentation. The threshold concentrations of nitrogen dioxide are often attained within 1 to 2 days and begin to decline gradually after 10 to 14 days but if the silos is well sealed, the gas may remain in there for weeks. Heavily fertilized silage, particularly the ones produced from immature plants, generate a higher concentration of the gas within the silo. Nitrogen dioxide is about 1.5 times heavier than air and during silage storage, nitrogen dioxide remains in the silage material. Improper ventilation may result in exposure during the leveling of the silage.
Sources: en.wikipedia.org
I have a fascination with how brainwashed people get with religion and how they'll give up their money, their time and their whole life for a cause that they're sure is right, but I'm sure is wrong. I think there's a lot of people who are scared of life and living and they want to make sure they get to Heaven or whatever. I try to stay away from it as much as I can. I was raised in the church until I was 16 and I've disagreed with their beliefs as long as I can remember, so when I had the choice I chose not to believe in anything apart from myself. Staley also stated in a 1999 interview that the song "Get Born Again" is about "religious hypocrisy". He approached music through his parents' collection, listening to Black Sabbath (regarded by him as his first influence) and Deep Purple. Other favorite bands include hard rock and metal bands like The Stooges, Anthrax, Judas Priest, Saxon, Rainbow, Mercyful Fate, Twisted Sister, Van Halen, and industrial/new wave acts such as Ministry, The Lords of the New Church and Skinny Puppy. He also cited Prince and David Bowie as two of his biggest idols. Staley began playing drums at age 12; he played in several glam bands in his early teens, but by this point, Staley had aspirations of becoming a singer. In 1984, Staley joined a group of Shorewood High students in a band called Sleze, which also featured future members of The Dehumanizers and Second Coming. In 1985, Staley and his band Sleze made a cameo in Father Rock, a low-budget movie from Seattle's Public Access Channel.
== Tourism == The World Economic Forum's Travel & Tourism Competitiveness Index 2017 Report, ranked Thailand 34 of 136 nations (1=most competitive, 136=least competitive). Other ASEAN nations ranked were: Singapore, 6; Malaysia, 26; Indonesia, 42; Vietnam, 67; Philippines, 79; Laos, 94; Cambodia, 101. International Tourist Arrivals and Receipts: Thailand ranked number nine in 2016, with 32.5 million arrivals. It ranked third in international tourism receipts, US$49.9 billion. Global Destinations Cities Index 2016: In this seventh annual survey published by MasterCard, Bangkok ranked number one of 100 cities worldwide as the top global destination city as determined by number of visitors. It displaced London, the previous number one. Other ASEAN cities ranked in the survey were Singapore, 6; Ho Chi Minh City, 42; Hanoi, 52; Jakarta, 66; and Manila, 74. Travel and Tourism Competitiveness Report 2015: Thailand ranked 35 of 141 nations. Among ASEAN nations, Singapore was ranked 11; Malaysia, 25: Indonesia, 50; Philippines, 74; Vietnam, 75; Laos, 96; Cambodia, 105; and Myanmar, 134. International Tourist Arrivals: Thailand ranked number ten in 2013, up five places from 2012 with 26.5 million arrivals. International Tourist Receipts: Ranked number seven in the world in 2013, up two places from 2012, with receipts estimated at US$42.1 billion. Total tourism contribution to GDP: Thailand ranked 18 of 184 nations in 2014, with travel and tourism income totalling 2,345 billion baht or 19.3 percent of GDP.
Harriet Jane Lawrence (September 13, 1883 – February 28, 1974) was an American physician and pathologist who was among the early women to specialize in laboratory medicine in the United States and the first known woman pathologist in Oregon. She earned her medical degree from Boston University School of Medicine in 1912 and established a clinical laboratory in Portland the following year, directing it for more than fifty years. During the 1918 influenza pandemic, Lawrence isolated hemolytic streptococcus from infected patients and developed a bacterial vaccine intended to combat secondary pneumonia associated with influenza. Although the viral cause of influenza was not yet understood, her work contributed to statewide treatment efforts and brought her national recognition. Over the course of her career, she supported the early medical career of Alan L. Hart and advocated for expanded opportunities for women in medicine.
=== Barcode-free hit discovery === Böcker, Pomplun, and colleagues developed a barcode-free hit discovery, wherein the small molecules serve as their own identifiers, acting as the ‘barcodes’ themselves. Known as the Self-Encoded Library (SEL) platform, this approach combines tandem mass spectrometry with custom software called COmbinatorial Mass Encoding Decoding Tool (COMET) for automated structure annotation. By removing the need for external tags, such as the bulky DNA sequences used in traditional DNA-encoded libraries (DELs), the platform eliminates potential interference with target binding and expands the range of compatible chemical reactions. The SEL platform enables direct screening of over half a million small molecules in a single experiment. This platform allowed scientists to identify binders for nucleic acid-binding targets like flap endonuclease 1 (FEN1), a DNA-processing enzyme overexpressed in multiple cancer types that was previously inaccessible to traditional DEL screenings. Furthermore, the platform democratizes drug discovery by utilizing standard mass spectrometry facilities and straightforward synthesis techniques that are accessible to smaller academic laboratories. There are some limitations to the SEL platform. Firstly, there is low scaffold diversity within individual libraries, as the chemistry is limited to the structures compatible with the COMET software. Additionally, SEL hits cannot be amplified, so the amount of material for each potential hit must account for the sensitivity limits of the mass spectrometer.
PCP has multiple routes of administration. Most commonly, the powder form of the drug is snorted. PCP can also be orally ingested, injected subcutaneously or intravenously, or smoked laced with marijuana or cigarettes.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.